/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
The development and long-term maintenance of heart failure with improved ejection fraction after a heart failure hospitalization: how are mortality rates affected?
Event: ESC Congress 2024
Topic: Epidemiology, Prognosis, Outcome
Session: Ejection fraction in heart failure: epidemiology, comorbidity, and quality of life
The implementation of modern guideline-directed medical therapy among hospitalized patients with heart failure with reduced ejection fraction: real-world experience from two tertiary cardiac centers
Event: ESC Congress 2024
Topic: Pharmacotherapy
Session: Optimal framework for heart-failure care
The eligibility of patients hospitalized for heart failure for rapid up-titration of guideline-directed medical therapy in the light of the STRONG-HF trial and the latest ESC heart failure guidelines
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: ePosters in chronic heart failure - pharmacotherapy 4
The incidence of severe heart failure among hospitalized patients with HFrEF. Do we have a simplified diagnostic criteria helping in the earlier diagnosis and better prognosis?
Event: Heart Failure 2024
Topic: Epidemiology, Prognosis, Outcome
Session: ePosters in chronic heart failure - epidemiology, prognosis, outcome 5
Optimization and long-term applicability of guideline-directed medical therapy based on kidney dysfunction after heart failure hospitalization: how are mortality and rehospitalization rates affected?
Event: Heart Failure 2023
Topic: Comorbidities
Session: ePosters in chronic heart failure 3
The applicability and effect on mortality of the implementation of guideline-directed pharmacological therapy among hospitalised patients with heart failure with reduced ejection fraction in 2019-2020
Event: Heart Failure 2022
Topic: Pharmacotherapy
Session: Heart Failure ePosters - focus on Chronic Heart Failure 5
